EXTENDED REPORT

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

H A Chen¹, K C Lin², C H Chen¹, H T Liao¹, H P Wang¹, H N Chang¹, C Y Tsai¹, C T Chou¹

¹ Section of Allergy-Immunology-Rheumatology, Department of Medicine, Veterans General Hospital-Taipei, Taiwan, and Department of Medicine, National Yang-Ming University, Taiwan
² National Taipei College of Nursing, Taiwan

Correspondence to:
Professor Chung-Tei Chou
Section of Allergy-Immunology-Rheumatology, Department of Medicine, Veterans General Hospital-Taipei, 201, Sec.2, Shih-Pai Road, 11217 Taipei, Taiwan; ctchou{at}vghtpe.gov.tw

Objective: To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis.

Methods: The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of them received etanercept as a twice weekly 25 mg subcutaneous injection for three months, and the others did not. Serum samples were collected at baseline and one month intervals during the treatment course. The serum levels of anti-CCP and RF were tested by enzyme linked immunosorbent assay and nephelometry, respectively.

Results: At baseline, 45 of the 52 etanercept treated patients (86.5%) and 32 of the 38 controls (84.2%) were positive for anti-CCP. Tests for RF were positive in 78.9% and 84.2% of patients with or without etanercept treatment, respectively. The serum levels of anti-CCP and RF decreased significantly after a three month etanercept treatment (p = 0.007 and p = 0.006, respectively). The average decrease from baseline calculated for each individual patient in the etanercept treated group was 31.3% for anti-CCP and 36% for RF. The variation in anti-CCP was positively correlated with the variation in disease activity, swollen and tender joint counts, RF, and C reactive protein.

Conclusions: Etanercept combined with DMARDs leads to a much greater decrease than DMARDs alone in the serum levels of anti-CCP and RF in rheumatoid arthritis, compatible with a reduction in clinical disease activity.

Abbreviations: CCP, cyclic citrullinated peptide; DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; ELISA, enzyme linked immunosorbent assay; ESR, erythrocyte sedimentation rate; IL, interleukin; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor

Keywords: etanercept; cyclic citrullinated peptide; rheumatoid factor; rheumatoid arthritis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• van Tuyl, L H D, Lems, W F, Kerstens, P J S M, Voskuyl, A E, Dijkmans, B A C, Boers, M (2009). IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis. Ann Rheum Dis 68: 1652-1653 [Full Text]  
• Bos, W H, Bartelds, G M, Vis, M, van der Horst, A R, Wolbink, G J, van de Stadt, R J, van Schaardenburg, D, Dijkmans, B A C, Lems, W F, Nurmohamed, M T, Aarden, L, Hamann, D (2009). Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Ann Rheum Dis 68: 558-563 [Abstract] [Full Text]  
• Pasquetti, P., Morozzi, G., Galeazzi, M. (2009). Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology (Oxford) 48: 315-316 [Full Text]  
• Coenen, D., Verschueren, P., Westhovens, R., Bossuyt, X. (2007). Technical and Diagnostic Performance of 6 Assays for the Measurement of Citrullinated Protein/Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis. Clin. Chem. 53: 498-504 [Abstract] [Full Text]  
• Bobbio-Pallavicini, F., Caporali, R., Alpini, C., Avalle, S., Epis, O. M, Klersy, C., Montecucco, C. (2007). High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor {alpha} inhibitors in rheumatoid arthritis. Ann Rheum Dis 66: 302-307 [Abstract] [Full Text]  
• Turesson, C, Jacobsson, L T H, Sturfelt, G, Matteson, E L, Mathsson, L, Ronnelid, J (2007). Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66: 59-64 [Abstract] [Full Text]  
• Avouac, J, Gossec, L, Dougados, M (2006). Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65: 845-851 [Abstract] [Full Text]